With only 12% 1 of therapies surviving the gauntlet of Phase III trials to receive FDA approval, and the cost to bring a drug ...
Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program ...
Former Eli Lilly Research Fellow Jeremy R. Graff, Ph.D., appointed as President and Chief Development Officer to lead the Company's clinical development programsEli Lilly and Celgene veteran Jose Igle ...